Drug Search Results
More Filters [+]

Cefdinir

Alternative Names: cefdinir, omnicef
Latest Update: 2024-06-28
Latest Update Note: Clinical Trial Update

Product Description

Cefdinir is used to treat certain infections caused by bacteria such as bronchitis (infection of the airway tubes leading to the lungs); pneumonia; and infections of the skin, ears, sinuses, throat, and tonsils.. Cefdinir is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a698001.html)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Bangladesh | Chile | Colombia | Ecuador | Egypt | India | Indonesia | Ireland | Jordan | Korea | Lebanon | Mexico | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Sweden | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cefdinir

Countries in Clinic: China

Active Clinical Trial Count: 5

Highest Development Phases

Phase 1: Abscess|Anthrax|Blepharitis|Bronchitis, Chronic|Carbuncle|Cellulitis|Cystitis|Erysipelas|Escherichia coli Infections|Folliculitis|Haemophilus Infections|Hidradenitis|Inflammation|Influenza, Human|Klebsiella Infections|Laryngitis|Lymphadenitis|Lymphangitis|Mastitis|Otitis Media|Otitis Media, Suppurative|Paronychia|Pharyngitis|Pneumonia|Pneumonia, Bacterial|Proteus Infections|Pyelonephritis|Pyoderma|Scarlet Fever|Sinusitis|Surgical Wound Infection|Tonsillitis|Urethritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20211160

P1

Not yet recruiting

Pharyngitis|Proteus Infections|Cystitis|Klebsiella Infections|Haemophilus Infections|Sinusitis|Paronychia|Pneumonia|Inflammation|Carbuncle|Escherichia coli Infections|Otitis Media, Suppurative|Bronchitis, Chronic|Lymphangitis|Influenza, Human|Hidradenitis|Cellulitis|Abscess|Anthrax|Pyoderma|Pyelonephritis|Scarlet Fever|Folliculitis|Erysipelas

None

CTR20202701

P1

Not yet recruiting

Tonsillitis|Influenza, Human|Pyoderma|Sinusitis|Klebsiella Infections|Cystitis|Haemophilus Infections|Scarlet Fever|Otitis Media|Laryngitis|Lymphadenitis|Pharyngitis|Bronchitis, Chronic|Proteus Infections|Pneumonia, Bacterial|Escherichia coli Infections|Pyelonephritis

None

CTR20130418

P1

Active, not recruiting

Escherichia coli Infections|Klebsiella Infections|Proteus Infections|Influenza, Human|Haemophilus Infections

None

CTR20130963

P1

Active, not recruiting

Cellulitis|Sinusitis|Hidradenitis|Klebsiella Infections|Paronychia|Carbuncle|Anthrax|Mastitis|Lymphangitis|Bronchitis, Chronic|Pyoderma|Pneumonia|Influenza, Human|Abscess|Cystitis|Escherichia coli Infections|Tonsillitis|Blepharitis|Urethritis|Erysipelas|Pharyngitis|Proteus Infections|Otitis Media, Suppurative|Pyelonephritis|Folliculitis

None

Recent News Events